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Xenopusimportant role during vertebrate cardiogenesis. Transcripts for the hyaluronan
synthase Has2 gene are expressed in heart anlage, and disruption of either Has2 or versican, a hyaluronan
matrix component, abrogates normal cardiac morphogenesis. However, the mechanisms by which hyalu-
ronan matrix contributes to early heart development are largely unknown. Here we show that Xenopus
hyaluronan and proteoglycan-binding link protein 3 (XHAPLN3) helps to maintain hyaluronan matrix around
the cardiac anlage, and thereby contribute to cardiogenesis. XHAPLN3 mRNA transcript localization
overlapped with the mRNA expression of both Xhas2 and Xversican at the heart anlage of early tailbud
(stage 23) embryos. Furthermore, knockdown of XHAPLN3 or Xhas2 with morpholino antisense oligos
caused a heart deﬁciency in developing tadpoles. Our results show when and how components of the
hyaluronan matrix function in cardiogenesis, improving our understanding of how extracellular matrix
participates in embryogenesis.
© 2008 Elsevier Inc. All rights reserved.Introduction
The heart is one of the earliest organs to form during vertebrate
embryogenesis (Brand, 2003). The genes and proteins that mediate
heart development have signiﬁcant potential in cardiomyocyte rege-
neration and therapy for congenital heart disease. Xenopus laevis
embryos are valuable research tools in this ﬁeld, because they are
available in large number, and are sufﬁciently large and robust to be
cultured after simple microsurgery. In addition, Xenopus eggs are also
fertilized externally and all stages of embryo development are easily
accessible, making it relatively easy to study the function of indivi-
dual gene products during heart development by microinjection into
embryonic cells. Blastomere-speciﬁc microinjection allows widely
expressed genes to be disrupted speciﬁcally in differentiating heart
tissue. Furthermore, heart function is entirely unnecessary until
tadpoles begin feeding, thus even treatments that severely disrupt
cardiogenesis can be studied (Mohun et al., 2003).
In Xenopus, cardiogenesis is initiated by the combined action of
Wnt antagonists from the Spemann organizer and several endo-(Biology), Graduate School of
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ima).
Graduate School of Science,
do 060-0810, Japan.
l rights reserved.dermal factors (Nascone and Mercola, 1995; Shi et al., 2000;
Schneider and Mercola, 2001). Cardiac progenitor cells are formed
bilaterally on mesodermal tissues adjacent to the Spemann organizer
during early gastrula stages. The presumptive cardiac mesoderm
extends laterally as neurulation proceeds, eventually fusing at the
ventral midline in the tailbud stage. Subsequent differentiation of
cardiac tissue and formation of the beating heart occurs in this
ventral location. The mechanisms by which the induced precardiac
anlage forms a beating and compartmentalized heart remain largely
unresolved. We originally set out to investigate genes involved in
cardiogenesis. We subsequently cloned the Xenopus hyaluronan
and proteoglycan-binding link protein 3 (XHAPLN3) gene, expressed
in the cardiac region during early embryogenesis. XHAPLN3 belongs
to the link-protein family, which comprises four members (HAPLN1–
HAPLN4). HAPLN proteins commonly have an aggrecan-family
binding domain and two hyaluronan-binding domains. In some ver-
tebrate species, HAPLN1 is expressed predominantly in cartilage,
while HAPLN2 and HAPLN4 expressions are restricted to the brain/
central nervous system, and HAPLN3 is widely expressed (Spicer et
al., 2003).
Hyaluronan is a simple straight-chain molecule comprising many
sugar units, either N-acetylglucosamine or glucuronate. Regardless
of simple composition of hyaluronan chain, it has several functions
(Spicer and Tien, 2004). One key role is in cartilage matrix organi-
zation, where hyaluronan serves as the backbone of the cartilage
proteoglycan aggregate, binding both link protein and aggrecan
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cular aggregates mediate the viscoelastic properties controlling the
osmotic pressure of cartilage matrix (Urban et al., 1979). Hyaluronan
also participates in angiogenesis, with the high and low molecular-
mass molecules possessing distinct functions. High molecular-mass
hyaluronan is inhibitory to angiogenesis (West and Kumar, 1988,
1989a, 1991), while oligohyaluronan is a potent inducer of angiogen-
esis via stimulation of endothelial cell proliferation (West and Kumar,
1989b; Deed et al., 1997), migration (Sattar et al., 1994), and sprout
formation (Montesano et al., 1996). Furthermore, hyaluronanmatrix is
found in chambered heart. Hyaluronan is synthesized by hyaluronan
synthase 2 (Has2) from the endocardium and an aggrecan-family
proteoglycan, versican, is secreted from the myocardium (Yamamura
et al., 1997; Mjaatvedt et al, 1998; Camenisch et al., 2000; Camenisch
et al., 2002). These components accumulate between the endo- and
myocardium, assembling into a large hydrated matrix called cardiac
jelly, which in turn facilitates endocardial cell migration. Hyaluronan
also promotes the Ras-dependent transformation into heart valve
mesenchyme. In fact, most of what we know about hyaluronan comes
from studying the cardiac phenotype in Has2−/− mice or versican-
deﬁcient hdf mice embryos (Yamamura et al., 1997; Mjaatvedt et al,
1998; Camenisch et al., 2000; Camenisch et al., 2002). However,
the early embryonic death of the Has2−/− and hdf mouse models
doesn’t allow for the complete study of hyaluronan/versican during
cardiogenesis.
This study examined the spatiotemporal distribution of XHAPLN3
during early-phase Xenopus development. Moreover, we analyzed
XHAPLN3 function during early cardiogenesis by microinjecting a
morpholino antisense oligonucleotide (MO) for XHAPLN3 (XHAPLN3-
MO) into blastomeres already speciﬁed to become heart. Our ﬁnd-
ings indicated that XHAPLN3 is an essential gene in hyaluronan
matrix formation around the cardiac anlage and contributes to
cardiogenesis.
Materials and methods
Microarray
Ventral marginal zone (VMZ) explants were precipitated and incubated as
described previously (Schneider and Mercola, 2001). Total RNA was prepared from
500 pg dkk1 mRNA-injected VMZ and uninjected VMZ explants using the ProK-phenol
method (Ito et al., 2001). The Agilent Low RNA Input Fluorescent Linear Ampliﬁcation
Kit (Agilent) was used to synthesize ﬂuorescently labeled cRNA targets for microarray
analysis. Labeled cRNA targets were hybridized with the 8 K Xenopus laevis DNA
microarray, which was customized by Agilent Technologies to contain 8091 genes.
Sequence information for each probe was obtained from Xenopus laevis UniGene on
June 17, 2002 (http://www.ncbi.nlm.nih.gov/Unigene). The microarray was scanned by
an Agilent G256AA microarray scanner (Agilent), and the image was analyzed by
Feature Extraction Software (Agilent). We performed a color-swap experiment to
compensate for the dye-speciﬁc effect and to ensure statistically relevant data. The
hybridization datawas deposited in the Center for Information Biology Gene Expression
Database (CIBEX; http://cibex.nig.ac.jp/cibex2/index.jsp, accession number CBX51) in
accordance with MIAME convention.
RNA extraction and RT-PCR
Total Xenopus RNA was extracted as described previously (Ito et al., 2001). First-
strand cDNA synthesis and PCR analysis were performed as described previously (Nitta
et al., 2004). The primers used were as follows:Gene name PrimerXHAPLN3 for Fig. 2A Fw: 5′-GGGGAATACAAGGGGCGAGTG-3′
Rv: 5′-ACTCATCTTGTAGCAGTAGACACC-3′Nkx2.5 for Fig. 2A Fw: 5′-GAGCTACAGTTGGGTGTGTGTGGT-3′
Rv: 5′-GTGAAGCGACTAGGTATGTGTTCA-3′ODC for Fig. 2A; SFig. 2, 3 Fw: 5′-GTCAATGATGGAGTGTATGGATC-3′
Rv: 5′-TCCAATCCGCTCTCCTGAGCAC-3′Injected XHAPLN3 and Fw: 5′-GGGGAATACAAGGGGCGAGTG-3′
XHAPLN3d for SFig. 2 Rv: 5′-AATACGACTCACTATAG-3′Injected Xhas2 for SFig. 3 Fw: 5′-GTGCAGTTTTGGGGATGACCG-3′
Rv: 5′-AATACGACTCACTATAG-3′XHAPLN3, Xhas2, and Xversican cloning
EST clone IMAGE: 5572456 (GenBank Accession Number BC046259) corresponded
to the Xenopus orthologue of HAPLN3. X-HAS2_pCIneo was kindly donated by Dr. G.
Lepperdinger (Köprunner et al., 2000). EST sequences (UniGene Xl.24776) corre-
sponded to the Xenopus orthologue of versican.
The coding regions of XHAPLN3, Xhas2, and Xversican were subcloned into pBlue-
script II SK+ and used to prepare the in situ hybridization RNA probe. cDNA fragments
were PCR-ampliﬁed from an early tailbud cDNA (for XHAPLN3 and Xversican) or X-
HAS2_pCIneo (for Xhas2) using pfu turbo DNA polymerase (Stratagene). The following
primers were used to amplify cDNA fragments:Gene name PrimerXHAPLN3 Fw: 5′-ATGCTTGCCGAATTTGCTGTG-3′
Rv: 5′-TTAACTCATCTTGTAGCAGTAGAC-3′Xhas2 Fw: 5′-ATGCACTGTGAACGGTTTATATG-3′
Rv: 5′-TCAAGCAAGCACCAAGTCATG-3′Xversican Fw: 5′-TGTCCTCAATCAACTGTATGGCC-3′
Rv: 5′-CTTATGGTTGGCAAATGGCGC-3′Nkx2.5 Fw: 5′-ATGTTTGCCAGTCCTGTGACA-3′
Rv: 5′-CTACCAAGCTCGGATGCCATG-3′Cardiac troponin I Fw: 5′-CTAAAGAGCCTGGAGAAGATG-3′
Rv: 5′-AATCTCCCCTTCTTAAACTGC-3′Tbx5 Fw: 5′-ATGGCGGACACAGAGGAGGC-3′
Rv: 5′-TTAGCTGTTTTCATTCCAGTCTGGG-3′Myocardin Fw: 5′-GCATAGTGGTTCCCCGAATG-3′
Rv: 5′-ACTGAGGATCGTCATTACCGA-3′GATA4 Fw: 5′-ATGTATCAGAGTATAGCTATGG-3′
Rv: 5′-TTAAGCTAAGACCAGGTTGTTCC-3′Hex Fw: 5′-ATGCAGTACCAGCACCCCAGC-3′
Rv: 5′-TTAATGTGCACAGTTGTAATATCC-3′Embryo manipulation, whole-mount in situ hybridization, and TUNEL analysis
In vitro fertilization, embryo culture, staging, microinjection, in situ hybridization,
and sectioning were carried out as described previously (Ito et al., 2001). pBluescript-
Xsox17α was kindly donated by Dr. Hudson (Hudson et al., 1997). pGEM-Xlﬂi and
pBluescript II-SCLwere kindly donated by Dr. Inui (Inui et al., 2006). The cDNAs of Nkx2.5
(GenBank Accession Number L25600), cardiac troponin I (GenBank Accession Number
L25721), Tbx5 (GenBank Accession Number AF133036), myocardin (GenBank Accession
Number AY585230), GATA-4 (GenBank Accession Number U45453) and Hex (GenBank
Accession Number U94837) were subcloned as described above. These cDNAs were
used to prepare RNA probes for in situ hybridization. The above primers were used to
amplify cDNA fragments.
Terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-
labeling (TUNEL) analysis was carried out as described previously (Inui and Asashima,
2004). Positive control samples (Fig. 10C) were prepared from an adjacent section
shown in Fig.10B and treated with 1 U/μl DNaseI (Sigma), and then incubated for 10min
at room temperature prior to the TdT reaction step.
Antisense morpholino oligonucleotides
We identiﬁed 5′UTR sequences of XHAPLN3 and Xhas2 by 5′RACE. Morpholinos
(Gene Tools) were designed to both alleles of target mRNAs. Morpholino sequences
were as follows: XHAPLN3-MO, 5′-ATCACAGCAAATTCGGCAAGCATTG-3′; Xhas2-MO,
5′- ATAAACCGTTCACAGTGCATCTTGG-3′. We checked the morpholino activities and
speciﬁcities as described in Supplementary Materials.
Hyaluronan detection
Embryos were ﬁxed in 3.7% formaldehyde, 2 mM MgCl2, 1 mM EDTA, 0.5%
cetylpyridinium chloride in 100 mM PIPES (pH 6.8) (CPC-PEMFA), dehydrated in
ethanol, and then embedded in parafﬁn (Köprunner et al., 2000). After sectioning,
rehydrated specimens were treated according to the Streptavidin/Biotin Blocking Kit
(Vector Laboratories) and blocked in 3% BSA/PBS. Hyaluronan detectionwas carried out
by incubation with a biotinylated hyaluronan-binding protein (Seikagaku) for 12 h at
4 °C, followed by AlexaFluor®488-conjugated Streptavidin (Molecular Probes). Injected
samples were traced by AlexaFluor®594-conjugated dextran (Molecular Probes).
For hyaluronan quantiﬁcation, ten precardiac regions were collected and homo-
genized in 100 μl Tris–Cl (10 mM, pH 8.0). Part of this homogenate was analyzed by DC
Protein Assay (Bio-Rad) to normalize the samples for amount of hyaluronan. The
remaining homogenate was incubated with Actinase E (Kaken Pharmaceuticals) at a
ﬁnal concentration of 2.5% for 24 h at 55 °C, boiled for 10 min, and then centrifuged at
12,000 rpm. Hyaluronan in the supernatant was measured using the Hyaluronan Assay
Kit (Seikagaku). Negative controls were prepared by incubating the homogenate with
Hyaluronidase SD (Seikagaku) at a ﬁnal concentration of 1 U/nl for 10 min at 37 °C prior
to the Actinase E treatment.
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Isolation of XHAPLN3
An initial cDNA microarray screen identiﬁed novel genes
expressed during Xenopus cardiogenesis. Speciﬁcally, this screen
targeted genes induced by the Wnt antagonist dkk1, which initiates
cardiogenesis in X. laevis (Schneider and Mercola, 2001), and dkk1-
injected VMZ is a valuable induction system for studying cardio-
genesis. Genes upregulated by more than 1.5-fold in dkk1-injected
VMZ were identiﬁed as candidates (Supplementary Table 1). Whole-
mount in situ hybridization analysis of positive clones from the
array screen identiﬁed one gene expressed in the precardiac ﬁeld
of neurula-stage embryos. Amino-acid sequence prediction re-
vealed this gene to be the Xenopus ortholog of HAPLN3 (Spicer et
al., 2003), thus designated XHAPLN3 (Fig. 1A). As with other link-Fig.1.HAPLN3 sequence alignment and identities. (A) Alignment of HAPLN3 protein sequence
zebraﬁsh (accession no. BC068325). Identical residues are indicated in red. The yellow box (
cbs.dtu.dk/services/SignalP/). Blue boxes (IG) represent the immunoglobulin domain. The tw
model for the XHAPLN3–proteoglycan–hyaluronan complex structure. Blue lines represent t
the hyaluronan chain. Pink lines represent glycosaminoglycan.protein family members, XHAPLN3 has an N-terminal signal se-
quence followed by an immunoglobulin (Ig) domain and two con-
secutive proteoglycan tandem-repeat (PTR) domains (Fig. 1A).
Previous studies indicated that XHAPLN3 binds to proteoglycans of
the aggrecan family via the Ig domain (blue) and to hyaluronan
(orange) via the PTR domains (green) (Spicer et al., 2003) (Fig. 1B).
Hence, XHAPLN3 was predicted to be an extracellular hyaluronan
matrix component.
XHAPLN3 is expressed in precardiac mesoderm
To investigate the possible role of XHAPLN3 in cardiogenesis, we
examined its relationship with early cardiac marker gene, Nkx2.5,
during Xenopus embryogenesis (Tonissen et al., 1994). XHAPLN3 and
Nkx2.5 transcripts were ﬁrst detected at the late gastrula stage
(stage 12; Fig. 2A). Both transcripts continued to be expresseds from Xenopus, human (accession no. AY262759), mouse (accession no. AY262757), and
SP) represents the signal peptide domains predicted by SignalP 3.0 server (http://www.
o green boxes (PTR1 and PTR2) represent proteoglycan tandem repeats. (B) Postulated
he immunoglobulin domain. Green lines represent PTR domains. Orange line represents
Fig. 2. Developmental expression proﬁles of XHAPLN3 and Nkx2.5. (A) RT-PCR analysis of XHAPLN3 and Nkx2.5 expression during Xenopus development. Ornithine decarboxylase
(ODC) served as a control. Reverse transcriptase negative (ODC (-RT)) reactions showed absence of genomic DNA contamination. (B–K, B′–K′) Whole-mount in situ hybridization of
XHAPLN3 and Nkx2.5. Nkx2.5 expression indicates heart region. (B–E, J, K) Ventral views with anterior toward the left. (F–I) Lateral views with anterior toward the left and dorsal
upwards. (B′–K′) Transverse sections of panels B–K embryos taken at respective positions of red lines in panels B–K. (B′–G′, J′, K′) Dorsal upwards. (H′, I′) Dorsal toward the left. so,
somite; ov, otic vesicle; ea, eye anlage; PCM, precardiac mesoderm; EC, endocardium;MC, myocardium; A, atrium; BC, bulbus cordis; V, ventricle. Scale bars in B–K and B′–K′ indicate
0.5 mm and 0.1 mm, respectively.
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mount in situ hybridization revealed XHAPLN3 transcripts in the
bilateral areas of Nkx2.5 expression shortly after gastrulation was
complete (stage 13; Figs. 2B, C, B′, C′). By the late neurula (stage 18)
and early tailbud (stage 23) stages, both genes were expressed in
precardiac mesoderm (Figs. 2D–G, D′–G′). At the late tailbud stage
(stage 34), when cardiac tube is forming, XHAPLN3 was expressed in
the endocardium (Figs. 2H, H′), while Nkx2.5 transcripts appeared
predominantly in the myocardium (Figs. 2I, I′). In tadpoles (stage
43), the heart has become a looped tube with separate chambers. By
this stage, XHAPLN3 was strongly expressed in the bulbus cordis
(Figs. 2J, J′), whereas Nkx2.5 mRNA was detected throughout the
heart structure (Figs. 2K, K′). These observations suggested that
XHAPLN3 acts at several steps of cardiogenesis. XHAPLN3 transcripts
were also detected in somite, otic vesicle, and eye anlage during earlyembryogenesis (Figs. 2F, H), further implicating this gene in roles
distinct from cardiac formation.
Knockdown of XHAPLN3 ablates heart formation
To examine whether ectopic expression of XHAPLN3 was sufﬁcient
for cardiogenesis, we injected mRNA encoding wild-type XHAPLN3
into dorsal or ventral blastomeres at the 4-cell stage and observed
phenotypes. Importantly, overexpression of 1 ng XHAPLN3 mRNA per
embryo induced neither malformation nor upregulation of Nkx2.5
(data not shown). If XHAPLN3 is indeed involved in cardiogenesis in
vivo, inhibition of its activity should repress cardiac formation in
embryos. XHAPLN3-MO was designed to speciﬁcally inhibit XHAPLN3
mRNA translation (Supplementary Figs. 2A, B), with the optimal
XHAPLN3-MO concentration determined in independent pilot expe-
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tion, whereas lower doses induced overt developmental defects.
XHAPLN3-MO was injected at the 8-cell stage into the dorsal region
of two dorsal–vegetal blastomeres fated to be heart anlage (Fig. 3A).
The MO-injected embryos were processed for in situ hybridization
and for observation of phenotype. The heart phenotype at stage 42Fig. 3. Loss of XHAPLN3 affects cardiogenesis. (A) Schema of bilateral injection
experiment. Eight-cell-stage Xenopus embryos were bilaterally microinjected with
30 ng of XHAPLN3-MO. (B–M)Whole-mount in situ hybridization of Nkx2.5 and cardiac
troponin I (cTnI). (B, C, J, K) Ventral views with anterior upwards. (D, E) Ventral views
with anterior toward the left. (F, G) Lateral views with anterior toward the left and
dorsal upwards. (H, I, L, M) Transverse sections of panels F, G, J, K embryos taken at
respective positions of red lines. Dorsal upwards. Asterisk indicates archenteron. Scale
bars in panels “B–G, J, K” and “H, I, L, M” indicate 0.5 mm and 0.1 mm, respectively. The
number of photo-presenting phenotype per total number of injected embryos is
indicated at upper right of each panel.was classiﬁed into three types: normal size, small size, and loss
(Supplementary Fig. 1).
At stage 13, Nkx2.5 expression in XHAPLN3-MO-injected
embryos was similar to that in uninjected embryos (Figs. 3B, C),
but decreased thereafter in the injected embryos (Fig. 3E)
compared to uninjected embryos (Fig. 3D) at stage 23. By stage
34, XHAPLN3-MO-injected embryos still showed weak Nkx2.5
expression (Fig. 3G). At this stage, sections of uninjected embryos
showed the tubular heart structure (Fig. 3H, arrowhead). In
contrast, sectioning of XHAPLN3-MO-injected embryos at stage
34 revealed chaotic, yolk-rich cells (eosin-positive) and no tubular
heart structure (Fig. 3I, arrowhead). XHAPLN3-MO was then
injected into the right-half blastomere for a detailed temporal
analysis of Nkx2.5 expression from the gastrula (stage 12) to the
tailbud (stage 28) stage (Fig. 4). XHAPLN3 depletion decreased
Nkx2.5 expression at the injected side at the early tailbud stage.
Moreover, uninjected embryos showed a steadily beating heart at
stage 42 (Supplementary Movie 1), as well as cardiac troponin I
(terminal differentiation marker) (Drysdale et al., 1994) transcripts
(Fig. 3J). At the same time, expression of cardiac troponin I was lost
in XHAPLN3-MO-injected embryos (Fig. 3K), and beating was
absent in many embryos (Supplementary Movie 2). Sectioning of
these embryos revealed that uninjected embryos had atrium-
ventricle separated heart (Fig. 3L, arrowhead), but that XHAPLN3-
MO-injected embryos had yolk-rich tissue instead of heart (Fig.
3M, arrowhead). This phenotype was not induced by injection of
the negative control MO (Supplementary Table 2), and was rescued
by coexpression of XHAPLN3 mRNA lacking the MO-binding
sequence (Supplementary Fig. 2C), indicating that the XHAPLN3-
MO effect was speciﬁc. Taken together, these results suggested
that signiﬁcant developmental steps in cardiogenesis occur during
the early tailbud stage and that XHAPLN3 contributes to this
development.
Xversican and Xhas2 expression overlap with XHAPLN3
Next, we analyzed the XHAPLN3-induced hyaluronan matrix
formed around precardiac mesoderm at the early tailbud stage. As
shown in Fig. 1B, XHAPLN3 may aggregate with both hyaluronan and
proteoglycan. Hyaluronan is a key glycosaminoglycan in embryonic
extracellular matrix (ECM) with predicted structural, hydrophilic, and
signaling roles. Vertebrate hyaluronan biosynthesis is governed by
three catalytic enzymes at the plasma membrane: Has1, Has2, and
Has3 (Spicer and Tien, 2004). The Xenopus orthologue Xhas2 is
expressed in heart anlage (Köprunner et al., 2000; Nardini et al.,
2004), implicating an association between Xhas2 and XHAPLN3.
Vertebrates express four aggrecan-family proteoglycans: aggrecan,
versican, brevican, and neurocan (Spicer and Tien, 2004). Until now,
the expression patterns of these genes in Xenopus heart anlage were
unclear. Hapln3 has been colocalized with versican in rat arterial
smooth muscle cells (Ogawa et al., 2004), and knockout of versican
caused defective cardiogenesis in mice (Mjaatvedt et al., 1998). Thus,
the Xenopus orthologue of versican, Xversican, was proposed to
function with XHAPLN3 during cardiogenesis. Whole-mount in situ
hybridization revealed weak expression of both Xhas2 and Xversican
in the precardiac region until stage 18 (Figs. 5A, B, A′, B′), and
expression of both genes in precardiac mesoderm by stage 23 (Figs.
5C, D, C′, D′). At stage 34, Xhas2 was expressed mainly in endo-
cardium (Figs. 5E, E′), while Xversican was detected in myocardium
(Figs. 5F, F′). Colocalization of XHAPLN3, Xhas2, and Xversican
suggested that these components aggregate to form the hyaluronan
matrix and function around precardiac mesoderm at stage 23.
Moreover, both Xhas2 and Xversican transcripts were present in the
somite (Figs. 5C–F), as was XHAPLN3, suggesting that the same
mechanism underlying hyaluronan matrix formation around pre-
cardiac mesoderm operates around somitic cells.
Fig. 4. Determining the stage of XHAPLN3-MO effect. (A) Schema of unilateral injection experiment. Eight-cell-stage Xenopus embryos were unilaterally microinjected with 15 ng of
XHAPLN3-MO. (B-D) Whole-mount in situ hybridization of Nkx2.5. Arrowhead indicates the injected side. Nkx2.5mRNA expression was unchanged at stage 17 (B), but decreased at
stages 23 and 28 (C, D). (E) Experimental summary showing that XHAPLN3-MO had an effect from the early tailbud stage.
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To address the function of the hyaluronan matrix during cardio-
genesis, an Xhas2-MO was designed to speciﬁcally inhibit Xhas2
mRNA translation (Supplementary Figs. 3A, B) and analyzed as for the
XHAPLN3-MO (Fig. 3A). Expression of both Nkx2.5 and cardiac
troponin I was decreased or lost in embryos injected with 40 ng
Xhas2-MO, as observed in XHAPLN3-MO-injected embryos. In Xhas2-
MO-injected embryos, Nkx2.5 expression was similar to that in
uninjected embryos at stage 13 (Figs. 6A, B), but decreased at stageFig. 5. Xhas2 and Xversican affect cardiogenesis in combinationwith XHAPLN3. (A, B) Ventral
dorsal upwards. (A′–F′) Transverse sections of panels A–F embryos taken at respective positi
precardiac mesoderm; EC, endocardium; MC, myocardium. Scale bars in panels A–F and A′–23 (Fig. 6D) and stage 34 (Fig. 6F) compared with uninjected embryos
(Figs. 6C, E). As with XHAPLN3-MO, loss of cardiac troponin I was
observed in Xhas2-MO-injected embryos at stage 42 (Fig. 6J), and
beating heart was absent (Supplementary Movie 3). Sectioning of
these embryos revealed that uninjected embryos had normal heart
structures (Figs. 6G, K, arrowhead), but that Xhas2-MO-injected
embryos showed only yolk-rich tissue in place of heart (Figs. 6H, L,
arrowhead). This phenotype was rescued by coexpression of Xhas2
mRNA lacking the MO-binding sequence (Supplementary Fig. 3C),
indicating that the Xhas2-MO activity was speciﬁc. These resultsviewswith anterior toward the left. (C–F) Lateral viewswith anterior toward the left and
ons of red lines. (A′–D′) Dorsal upwards. (E′, F′) Dorsal toward the left. so, somite; PCM,
F′ indicate 0.5 mm and 0.1 mm, respectively.
Fig. 6. Loss of Xhas2 affects cardiogenesis. Eight-cell-stage Xenopus embryos were
bilaterallymicroinjected with 40 ng of Xhas2-MO.Whole-mount in situ hybridization of
Nkx2.5 and cardiac troponin I (cTnI). (A, B, I, J) Ventral views with anterior upwards.
(C, D) Ventral views with anterior toward the left. (E, F) Lateral views with anterior
toward the left and dorsal upwards. (G, H, K, L) Transverse sections of panels E, F, I, J
embryos taken at respective positions of red lines. Dorsal upwards. Asterisk indicates
archenteron. Scale bars in panels “A–F, I, J” and “G, H, K, L” indicate 0.5 mm and 0.1 mm,
respectively. The number of photo-presenting phenotype per total number of injected
embryos is indicated at the upper right of each panel.
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during early embryogenesis. Moreover, coinjection of low doses of
XHAPLN3-MO and Xhas2-MO, each of which had little effect alone,
signiﬁcantly affected the embryos (Fig. 7A). Further, heart formation
was impaired by knockdown of both MOs. The effect of XHAPLN3-MO
was rescued by coexpression of 100 pg pCS2-XHAPLN3/5mis plasmid
but not by 100 pg pCS2-Xhas2/5mis, and vice versa (Fig. 7B). Taken
together, these results indicated that XHAPLN3 and Xhas2 function
during the same step of cardiogenesis, each being indispensable for
the other.
Figs. 3, 4, and 6 demonstrate that Nkx2.5 expressionwas decreased
or lost from the early tailbud stage, and that heart was lost at stage 42.
We therefore examined whether Nkx2.5 could rescue the respective
effects of XHAPLN3 and Xhas2 MO injection. Indeed, coexpression of
100 pg pCS2-Nkx2.5 plasmid rescued the loss of heart (Fig. 8). This
result implicated knockdown of XHAPLN3 and Xhas2 via Nkx2.5
down-regulation in the loss of beating heart.Knockdown of XHAPLN3 and Xhas2 results in expansion of endoderm
and endothelium
Next, we examined several marker-gene expressions around the
precardiac region at stage 23 to clarify the fate of the precardiac
mesoderm. Both XHAPLN3-MO and Xhas2-MO were injected at the 8-
cell stage into the dorsal region of two dorsal–vegetal blastomeres (Fig.
3A). Tbx5 (Horb and Thomsen, 1999) andmyocardin (Small et al., 2005)
play essential roles in cardiogenesis. At stage 23, these genes were
expressed in precardiac mesoderm in uninjected embryos (Figs. 9A, D),
while both MO-injected embryos had lost expression (Figs. 9B, C, E, F).
GATA4 (Kelley et al., 1993) was expressed in cardiac anlage and anterior
endoderm in control embryos (Fig. 9G),while its expressionwas slightly
expanded posteriorly in both MO-injected embryos (Figs. 9H, I). Pan-
endodermal marker Sox17α (Hudson et al., 1997) was expressed in the
endodermwithout injection (Fig. 9J), but surprisingly, the MO-injected
embryos showed strongectopic expression inpresumptive heart anlage
(Figs. 9K, L, arrowhead). Hex (Newman et al., 1997) was expressed in
developing liver (Fig. 9M, arrowhead), and this gene expressionwas lost
following either MO injection (Figs. 9N, O). The expression domain of
Xlﬂi (Meyer et al., 1995), an endothelial precursor cell marker, was
expanded laterally in MO-injected embryos (Figs. 9Q, R, arrowhead)
compared to uninjected embryos (Fig. 9P, arrowhead),while expression
of hematopoietic precursor cell marker gene SCL (Mead et al., 1998; Fig.
9S) was decreased at the anterior ventral blood island in injected
embryos (Figs. 9T, U, asterisk). In contrast, expression of Xversicanwas
unaffected by injection of either MO (Figs. 9V, W, X).
The pattern of apoptosis in precardiac mesoderm was also
examined by injecting XHAPLN3-MO and Xhas2-MO into the right-
half blastomere (Fig. 4A). Those embryos were ﬁxed and sectioned at
stage 23 for TUNEL analysis. Few TUNEL-positive cells were apparent
at the injected side (Figs. 10A, B, arrowhead), as observed on the
uninjected side (Figs. 10A, B, arrow). These results suggested that
knockdown of XHAPLN3 and Xhas2 differentiates presumptive heart
cells into some endoderm tissue and endothelial cells.
XHAPLN3 maintains hyaluronan matrix
Finally, we veriﬁed the contribution of XHAPLN3 to hyaluronan
matrix. To analyze the status of this matrix at the early tailbud stage,
XHAPLN3-MO or Xhas2-MO was injected into one dorsal–vegetal
blastomere with red-ﬂuorescent dye. Hyaluronan was then detected
with a biotinylated hyaluronan-binding protein. Both MOs were in-
jected into the dorsal side of blastomeres with a precardiac mesoderm
fate (Fig. 11A), resulting in loss of hyaluronan staining (Figs. 11B, B′, C,
C′). Both MOs were also injected into the lateral side of blastomeres
with a somitic fate (Fig. 11D), with similar results (Figs. 11E, E′, F, F′).
Moreover, to quantify the level of hyaluronan around precardiac
mesoderm, XHAPLN3-MO and Xhas2-MO were injected together into
two dorsal–vegetal blastomeres (Fig. 3A). The precardiac region was
manually isolated from stage 23 embryos and analyzed for hyaluronan
concentration (Fig. 11G). The amount of hyaluronan was decreased in
precardiac regions from MO-injected embryos compared to unin-
jected controls (Fig. 11H). Since Xhas2 would have synthesized
hyaluronan in the XHAPLN3-MO-injected embryos, these results
suggested that XHAPLN3 helps to maintain the hyaluronan matrix
around precardiac mesoderm and thereby contributes to cardio-
genesis. Moreover, XHAPLN3 plays the same role around the somite,
suggesting that a general mechanism may operate.
Discussion
XHAPLN3 expresses precardiac mesoderm
This study demonstrated XHAPLN3 mRNA expression in the
cardiac region, somite, otic vesicle, and eye anlage during early Xe-
Fig. 7. XHAPLN3-MO and Xhas2-MO act synergistically. (A) Summary of the frequencies of heart malformations in synergistic experiment with XHAPLN3-MO and Xhas2-MO. (B)
Summary of the crossing rescue experiments showing the effect of XHAPLN3-MO and Xhas2-MO injection on heart formation.
41Y. Ito et al. / Developmental Biology 319 (2008) 34–45nopus embryogenesis. Multiple-tissue-expression arrays in previous
studies localized human Hapln3 mRNA in several adult organs,
particularly the cardiovascular system, lymph nodes, and mammary
glands (Spicer et al., 2003; Ogawa et al., 2004). In contrast, rat Hapln3
mRNA is strongly expressed in aorta and skeletal muscle, but much
less in heart (Ogawa et al., 2004). Four link-protein family sequences
were identiﬁed in vertebrates, all showing a similar structure and
organization with an N-terminal signal sequence followed by an IgFig. 8. Loss of XHAPLN3 and Xhas2 was rescued by Nkx2.5. Graph showing heart malform
Xhas2-MO.domain and two consecutive PTR domains (Spicer et al., 2003).
During chick embryogenesis, cartilage link protein 1 (Crtl1)/Hapln1 is
abundant in cartilage and also present in a range of embryonic
noncartilaginous tissues including heart (Binette et al., 1994). It is
therefore predicted that link proteins are functionally redundant
during cardiogenesis in some vertebrates. The MO experiments in this
study indicated a signiﬁcant role for XHAPLN3 in Xenopus early
cardiogenesis.ation frequencies in experiments using Nkx2.5 to rescue effect of XHAPLN3-MO and
Fig. 9. Loss of XHAPLN3 and Xhas2 effect around precardiac region. Tbx5 (A–C), myo-
cardin (D–F), GATA4 (G–I), Sox17α (J–L), Hex (M–O), Xlﬂi (P–R), SCL (S–U), and Xversican
(V–X) mRNA expressions at stage 23. Ventral views with anterior toward the left. Scale
bars indicate 0.5 mm. The number of photo-presenting phenotype per total number of
injected embryos is indicated at the upper right of each panel.
42 Y. Ito et al. / Developmental Biology 319 (2008) 34–45Contribution of XHAPLN3 to hyaluronan matrix
XHAPLN3, Xhas2, and Xversican expressions overlapped spatially
at several regions during early embryogenesis in this study (Figs. 2
and 5). Moreover, XHAPLN3 and Xhas2 coordinately function
in cardiogenesis (Fig. 7A). Three hyaluronan synthases (Has1, Has2,
and Has3) have been detected in hypertrophic chondrocytes of
mammalian cartilage (Takada et al., 1999; Hiscock et al., 2000), and
hyaluronan synthesis plays a central role in organizing the cartilage
ECM together with aggrecan and Crtl1/Hapln1 (Watanabe and
Yamada, 1999). Another aggrecan protein, versican, also binds to
both hyaluronan and Crtl1/Hapln1 (Matsumoto et al., 2003), sug-gesting that some hyaluronan matrices contain three components:
hyaluronan, an aggrecan-family proteoglycan, and a link protein.
Colocalization of XHAPLN3, Xhas2, and Xversican therefore suggested
that these components aggregate to form the hyaluronan matrix and
function together around precardiac mesoderm and somites at the
early tailbud stage (particularly stage 23). Previous studies on mouse
atrioventricular canal morphogenesis also localized has2 and versi-
can expression in myocardium and endocardium, respectively,
implicating these molecules in forming the endocardial cushion
(Yamamura et al., 1997; Mjaatvedt et al., 1998; Camenisch et al.,
2000; Camenisch et al., 2002). The expression patterns of Xhas2 and
Xversican during Xenopus heart chamber formation in the current
experiments were similar to those observed in mouse (Fig. 5).
Moreover, XHAPLN3 was detected in endocardium, suggesting that
the components of cardiac jelly formation are conserved between
frog and mouse.
What then are the biochemical properties of XHAPLN3? Our
experiments show that XHAPLN3 depletion isn’t rescued by Xhas2
overexpression (Fig. 7B), suggesting that XHAPLN3 is indispensable
for establishment of hyaluronan matrix and for cardiogenesis.
Previous work implicated other link proteins in different tissues in
strengthening the proteoglycan–hyaluronan bond. In this mechanism,
the link proteins form a ternary complex involving both an interaction
with hyaluronanmediated by the two PTRmodules and an interaction
with the proteoglycan through the Ig-folds (Heinegård and Hascall,
1974; Hardingham, 1981; Binette et al., 1994; Shi et al., 2004; Seyfried
et al., 2005). It is known that aggregates formed in the presence of link
proteins do not dissociate signiﬁcantly at physiological ionic strength
and pH, and that addition of proteoglycans favors pericellular
hyaluronan matrix formation by increasing matrix density and thus
potentially matrix stability (Knudson and Knudson, 1993; Lee et al.,
1993). Cofunctioning of XHAPLN3 and Xversican could thus stabilize
the hyaluronan synthesized by Xhas2 to maintain the matrix around
precardiac mesoderm and somites.
Role of hyaluronan matrix for cardiogenesis
In this study, we demonstrated that Nkx2.5 expression was
decreased by region-speciﬁc knockdown of XHAPLN3 or Xhas2 with
MOs from early tailbud stage (Figs. 3 and 6). Moreover, at stage 23,
MOs injected embryos lost the expression of Tbx5 and myocardin
genes (Figs. 9B, C, E, F). Tbx5 and myocardin play a crucial role in
cardiac gene expression as transcription factor with Nkx2.5 (Hiroi et
al., 2001; Chen and Schwartz, 1996). Nkx2.5 is required for Tbx5 and
myocardinmRNA expression (Sun et al., 2004; Ueyama et al., 2003). In
our study, Nkx2.5 overexpression rescued the loss of heart by MOs
injection (Fig. 8). These ﬁndings suggest that loss of hyaluronan
matrix caused the down-regulation of Nkx2.5, caused the down-
regulation of other essential transcription factors for cardiogenesis,
and consequently induced loss of heart. GATA4 is also necessary for
cardiogenesis (Latinkić et al., 2003). This expression was observed in
anterior ventral region in MOs-injected embryos (Figs. 9H, I). GATA4
gene has Forkhead-, GATA-, and Smad-binding site and is regulated
by these transcription factors (Rojas et al., 2005). So regulation of
GATA4 at stage 23 may be independent of Nkx2.5. GATA4 mRNA is
also strongly detected in anterior endoderm (Kelly et al., 1993),
suggesting that there remains the endodermal expression of this
gene.
Sectioning of MOs-injected embryos revealed chaotic, yolk-rich
cells (eosin-positive) (Figs. 3I, 3M, 6H, 6L arrowhead). Moreover, the
MOs-injected embryos showed strong ectopic Sox17α expression in
presumptive heart anlage (Figs. 9K, L, arrowhead). At stage 23, it is
indicated that presumptive cardiac cells existingMOsmigrates normal
position (Figs. 11B′, C′) and doesn’t undergo apoptosis (Figs. 10A, B).
These ﬁndings suggest that presumptive heart anlage isn’t lost but
transform some endodermal tissue. However, liver marker gene Hex
Fig. 10. Loss of XHAPLN3 and Xhas2 does not induce apoptosis. XHAPLN3-MO (A) or Xhas2-MO (B) was injected into one dorsal–vegetal blastomere. Injected side and uninjected side
are indicated by an arrowhead and arrow, respectively. A positive control section (C) was prepared from an adjacent section shown in panel B by treating with 1 U/μl DNaseI. Three
photos were taken at the same exposure. Dorsal upwards. “N” and asterisk indicate notochord and archenteron, respectively.
43Y. Ito et al. / Developmental Biology 319 (2008) 34–45expression was lost in MOs-injected embryos (Figs. 9N, O). Previous
work said that signals from the cardiogenicmesoderm are required for
hepatogenesis (Jung et al., 1999), so the decline of cardiogenesis
resulted in the disruption of hepatogenesis.
Vascular and hematopoietic origins are close to precardiac
mesoderm (Inui et al., 2006). In our experiments, Xlﬂi, endothelial
precursor cell marker, was slightly expanded in MOs injected embryos
(Figs. 9Q, R, arrowhead). Previous studies said that high molecular-
mass hyaluronan is inhibitory in angiogenesis (West and Kumar, 1988;
West and Kumar, 1989a; West and Kumar, 1991), suggesting that
hyaluronan matrix around precardiac mesoderm inhibits the conver-
sion of precardiac mesoderm into endothelium. On the other hand,
SCL, hematopoietic precursor cell marker, was decreased at anterior
ventral blood island in MOs injected embryos (Figs. 9T, U, asterisk).
Potential role of hyaluronan was reported as mobilization of
hematopoietic cells (Pilarski et al., 1999). So migration of SCL positive
cells to anterior ventral region might be disrupted.
We demonstrated here that the hyaluronanmatrix is important for
cardiogenesis at the stage 23. Cardiac precursor cells are ﬁrst induced
in the gastrula, but beating heart is formed long after the cardiac
precursor induction, indicating that other activating factors are
necessary for the completion of cardiogenesis (Bruneau, 2002; Zaffran
and Frasch, 2002; Mohun et al., 2003). For instance, BMP signaling is
required to maintain Nkx2.5 gene expression at stages during and
after fusion of the bilateral heart primordial (Schultheiss et al., 1997;
Schlange et al., 2000; Shi et al., 2000; Walters et al., 2001). Sta-
bilization of hyaluronan matrix around precardiac mesoderm during
cardiogenesis may act either as the additional activating factor oneself
or as recruiter of other such factors. In the former, the cell-surface
hyaluronan receptor CD44 plays a major role in hyaluronan signaling.
However, the putative Xenopus CD44 orthologue is not expressed in
the cardiac region and its activity is not necessary for cardiogenesis
(Ori et al., 2006). In addition, mice deﬁcient for CD44 exhibit normal
cardiogenesis (Schmits et al., 1997; Wittig et al., 2000; Stoop et al.,
2001), suggesting that an alternative hyaluronan receptor might
operate in this situation. In the latter, versican, one of the hyaluronan
matrix component, has lectin-like domain, EGF-like domain, and
complement regulatory protein-like domain at the carboxyl-terminal
region (Ito et al., 1995). And the putative binding partners of these
domains remain unclear. Versican has many chondroitin sulfates at
the middle region (Ito et al., 1995). Chondroitin sulfate of versican has
highly oversulfated region (McGee and Wagner, 2003). Other over-
sulfated glycosaminoglycan, heparan sulfate has been previously
reported to modulate extracellular localization of a growth factor
(Reichsman et al., 1996), suggesting that chondroitin sulfate attached
to versican has same activity. Thus hyaluronan-versican-HAPLN3
complex might contribute to recruiting for some growth factors and
transducing the Nkx2.5-maintaining-signal, directly or indirectly.
Further studies are needed to clarify the involvement of ECM inembryogenesis. However, these ﬁndings hold promise for future
regenerative medicine endeavors in terms of improved scaffolds for
differentiating cardiomyocytes.
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